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Obesity can result in insulin resistance, hepatos-
teatosis, and nonalcoholic steatohepatitis (NASH)
and increases liver cancer risk. Obesity-induced
insulin resistance depends, in part, on chronic acti-
vation of mammalian target of rapamycin complex
1 (mTORC1), which also occurs in human and mouse
hepatocellular carcinoma (HCC), a frequently fatal
liver cancer. Correspondingly, mTORC1 inhibitors
have been considered as potential NASH and HCC
treatments. Using a mouse model in which high-fat
diet enhances HCC induction by the hepatic carcin-
ogen DEN, we examined whether mTORC1 inhibi-
tion attenuates liver inflammation and tumorigenesis.
Notably, rapamycin treatment or hepatocyte-spe-
cific ablation of the specific mTORC1 subunit Raptor
resulted in elevated interleukin-6 (IL-6) produc-
tion, activation of signal transducer and activator of
transcription 3 (STAT3), and enhanced HCC develop-
ment, despite a transient reduction in hepatosteato-
sis. These results suggest that long-term rapamycin
treatment, which also increases IL-6 production in
humans, is unsuitable for prevention or treatment of
obesity-promoted liver cancer.
INTRODUCTION
Rapamycin is a macrolide produced by the bacterium Strepto-
myces hygroscopicus found in a soil sample from Easter Island
(Ve´zina et al., 1975). Also known as sirolimus, rapamycin was
originally developed as an antifungal agent, but its potent immu-
nosuppressive activity was soon discovered and studied before
its mechanism of action was fully understood, resulting in its
FDA approval in 1999 for post kidney transplantation therapy.
The chief advantage of rapamycin over calcineurin inhibitors
is reduced kidney toxicity. Since then, rapamycin and severalderivatives, including everolimus and temsirolimus, collectively
referred to as rapalogs, were approved for a variety of indications
(Benjamin et al., 2011; Johnson et al., 2013). The target for these
drugs is the large (289 kDa) protein kinase target of rapamycin
(TOR) (Heitman et al., 1991), known asmTOR inmammals, which
forms two functionally distinct multiprotein complexes, mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Wulls-
chleger et al., 2006). mTORC1, composed of mTOR, raptor,
and mLST8, is a master regulator of cellular growth and meta-
bolism that is activated by nutrients and growth factors. Most
of the effects of rapamycin are due to inhibition of mTORC1
(Wullschleger et al., 2006). Accordingly, rapalogs are potent
suppressors of cellular proliferation and growth and can revert
several metabolic disorders, such as insulin resistance and hep-
atosteatosis, caused by persistent mTORC1 activation after hy-
pernutrition (Cornu et al., 2013; Du¨vel et al., 2010).
BecausemTORC1 is activated in well over 50%of human can-
cers (Menon andManning, 2008; Shaw andCantley, 2006), there
has been much interest in using rapalogs in cancer treatment
(Abraham andGibbons, 2007; Guertin and Sabatini, 2007; Saba-
tini, 2006). The mTOR pathway is also upregulated in up to 50%
of hepatocellular carcinomas (HCCs), the major form of liver
cancer, and phosphatase and tensin homolog (PTEN), the tumor
suppressor that inhibits mTORC1 activation, is inactivated in
many such tumors (Bhat et al., 2013; Hu et al., 2003). Moreover,
obesity, hepatosteatosis, and insulin resistance, pathologies
precipitated by hypernutrition and chronic mTORC1 activation,
are associated with a pronounced increase in HCC risk (Calle
et al., 2003). In fact, obesity is quickly becoming a major
driver of HCC, which together with nonalcoholic steatohepatitis
(NASH) is one of the most serious complications of hypernutri-
tion. Given the likely involvement of mTORC1 in hepatosteatosis
and cancer, it was suggested that rapalogsmay be useful in HCC
prevention and treatment (Bhat et al., 2013; Faloppi et al., 2011).
However, rapalogs had limited success as single-agent cancer
therapies in hundreds of clinical trials to date, and their activities
in most cancer types have been modest at best (Abraham and
Gibbons, 2007; Chiang and Abraham, 2007; LoPiccolo et al.,
2008). Clinical trials using rapalogs in HCC were also disap-
pointing; in a phase I/II study of everolimus, only one out ofCell Metabolism 20, 133–144, July 1, 2014 ª2014 Elsevier Inc. 133
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recently, a global phase III study showed that everolimus did
not extend overall survival compared to placebo in patients
with advanced HCC whose disease progressed while on or
after sorafenib treatment or who are intolerant to sorafenib
(ClinicalTrials.gov Identifier: NCT01035229) (Novartis, 2013a,
2013b). In addition, everolimus use for HCC treatment was found
to result in increased incidence of liver injury (Yamanaka et al.,
2013; Zhu et al., 2011).
These unexpected outcomes may be due to a poor under-
standing of the role of mTORC1 and the effect of its inhibition
in liver pathophysiology and tumorigenesis. In terms of liver
transplantation, NASH is now the third most common indication
in the US and the only indication consistently increasing in fre-
quency along with the alarming prevalence of the metabolic syn-
drome and its associated complications among liver transplant
recipients. If current trends continue, NASH will become the
most common indication for liver transplantation in the US within
10 to 20 years. Thus, it is particularly important to determine the
impact of rapalogs on hepatosteatosis, NASH, and other condi-
tions associated with the metabolic syndrome (Watt, 2012).
Curiously, despite its beneficial effects in kidney transplantation,
sirolimus is not recommended for use after liver transplantation
because of excess mortality, graft loss, and hepatic artery
thrombosis (HAT) (Massoud and Wiesner, 2012). Although ever-
olimus was approved in February 2013 for liver transplantation,
there seems to be a concern about its use for this indication
according to a recent clinical study that reported 13/245
(5.3%) deaths in the everolimus group compared to 7/243
(2.9%) deaths in the control group during the first 12 months of
use (full prescribing information of ZORTRESS [everolimus];
Reference ID: 3262062). Most deaths were associated with
liver-related issues, infections, and sepsis. Furthermore, the
incidence of hepatitis in old mice receiving long-term rapamycin
treatment was increased compared to controls, although it was
not significant because of a small sample size (Neff et al., 2013).
Such results stand in marked contrast to reports of rapamycin-
induced lifespan extension (Harrison et al., 2009; Johnson
et al., 2013), although follow-up studies discovered several
adverse effects of long-term rapamycin use (Lamming et al.,
2012; Neff et al., 2013).
In the present study, we used rapamycin treatment and liver-
specific raptor-deficient mice to determine the effect of systemic
and cell-type-specific mTORC1 suppression on liver physiology
and tumorigenesis. Although rapamycin reduced hepatosteato-
sis, it increased IL-6 production and activated the protumorigenic
factorSTAT3, resemblingeffects thatwereobserved inhumanpa-
tients (Buron et al., 2013). Furthermore, hepatocyte-specific loss
ofmTORC1activity resulted in low-grade liverdamageand inflam-
mation and a marked enhancement of hepatocarcinogenesis.
These results suggest that long-term mTORC1 inhibition may
not be a valid therapeutic option in NASH or steatotic HCC.
RESULTS
Rapamycin Reduces Hepatosteatosis but Increases IL-6
and STAT3
To examine whether mTORC1 inhibition reverses hepatosteato-
sis caused by high-fat diet (HFD), and thereby can reduce HCC134 Cell Metabolism 20, 133–144, July 1, 2014 ª2014 Elsevier Inc.risk, we placed male BL6 mice on normal chow or HFD for
3 months and then treated them with rapamycin while maintain-
ing the same feeding regimens. As expected, mice on HFD
exhibited marked hepatosteatosis, but 2 weeks of rapamycin
treatment decreased liver lipid droplets and reactive oxygen
species (ROS) content (Figures 1A and 1B). However, as previ-
ously observed in humans (Buron et al., 2013) and mice (Weich-
hart et al., 2008), rapamycin treatment enhanced liver damage
due to HFD feeding and increased IL-6 production, resulting
in activation of the oncogenic transcription factor STAT3 in liver
tissue (Figures 1C and 1D). Rapamycin treatment reduced
accumulation of the autophagy substrate p62, increased the
microtubule-associated protein 1 light-chain 3 (LC3) II:I ratio
(Figure S1A, available online), and decreased the mRNA expres-
sion of the lipogenic transcription factor SREBP1c, but it also
decreased expression of the anti-inflammatory cytokine IL-10
(Figure S1B). Thus, while enhancing autophagy, a beneficial
effect, rapamycin treatment also had adverse proinflammatory
effects. To determine whether strong mTORC1 inhibition leads
to hepatocyte death, we incubated a normal hepatocyte cell
line, AML12, with 10–100 mM of rapamycin. As found in other
cell types (Galluzzi et al., 2012; Yellen et al., 2011), 16 hr of incu-
bation with 10–100 mM of rapamycin resulted in considerable
cell death and caspase activation (Figures S1C–S1E).
Liver-Specific Raptor Knockout Mice
Some of the adverse effects observed in vivo could be due
to mTORC1 inhibition in cells other than hepatocytes, such as
macrophages (Mercalli et al., 2013; Weichhart et al., 2008). To
examine whether long-term mTORC1 inhibition in only liver
parenchymal cells circumvents these effects, we generated he-
patocyte-specific raptor-deficient mice (RaptorDhep) by crossing
RaptorF/F mice (Bentzinger et al., 2008) with Alb-Cre mice. Dele-
tion of the RaptorF allele was confirmed by PCR of genomic
DNA from isolated hepatocytes, although whole-liver tissue of
RaptorDhep mice retained some of the ‘‘floxed’’ allele due to the
presence of nonparenchymal cells (Figure 2A). Immunoblot anal-
ysis of RaptorDhep liver revealed a strong reduction in raptor pro-
tein (Figure 4F) and its complete absence in isolated hepatocytes
(Figure 2A). The amount of phospho-p70S6K (p-S6K), a major
mTORC1 substrate, was greatly reduced in RaptorDhep livers
(Figure 4F) and almost completely absent in isolated hepato-
cytes (Figure 2A). The amount of phospho-Ser473-PKB/AKT
(p-AKT) and its downstream targets, phospho-Ser21 and phos-
pho-Ser9- GSK3 (p-GSK3), were strongly elevated in RaptorDhep
livers (Figure 4F), indicating inhibition of mTORC1 activity and
hyperactivation of AKT due to loss of a negative feedback loop
(Bentzinger et al., 2008; Cornu et al., 2013). RaptorDhep mice
were obtained at the expected frequency and appeared healthy
after birth. Yet, at 2 months of age they showed signs of liver
injury (Figure 2B) and hepatocyte abnormalities, such as large
cells with enlarged and hyperchromatic nuclei (Figures 2C and
S2A). In addition, mild fibrotic changes (Figures 2C, S2B, and
S2C), immune cell infiltration (Figures 2C and 2D), hepatocyte
cell death, and p-gH2AX-positive hepatocytes, which implicate
DNA damage or stalled DNA replication forks (Figures 2E and
2F), were increased in RaptorDhep livers. Although Ki67- and
p-ERK-positive cells were not increased, cyclin D1-positive cells
were markedly elevated in RaptorDhep livers (Figure S2D).
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Figure 1. Rapamycin Treatment Enhances
IL-6 Expression and STAT3 Activation
Male mice (8 weeks old) kept on normal chow
(LFD) or high-fat diet (HFD) for 3 months were
treated with vehicle or rapamycin (5 mg/kg/d, i.p.)
for 2 weeks. During rapamycin treatment, the
same feeding regimens were continued. Livers
were collected and analyzed.
(A) Frozen liver sections were stained for lipid
droplets and ROS accumulation with oil red O
(ORO) and dihydroethidium (DHE), respectively
(magnification: 2003).
(B) Data from mice in (A) were quantitated with
ImageJ software and averaged (n = 3–4).
(C) Serum ALT and IL-6 were measured by Infinity
reagent and ELISA, respectively (n = 3–4).
(D) Livers were homogenized, and STAT3 and
p70S6K expression and phosphorylation were
analyzed by immunoblotting.
All the bar graphs in Figure 1 represent means ±
SD. See also Figure S1.
Cell Metabolism
Raptor Ablation, Liver Damage, and TumorigenesisLoss of Raptor Impairs Hepatocyte Proliferation and
Mitosis
mTORC1 was reported to regulate cell cycle and liver regenera-
tion (Espeillac et al., 2011), promoting G2/M transition and
mitosis (Gwinn et al., 2010; Nakashima et al., 2008; Ramı´rez-
Valle et al., 2010). To investigate hepatocyte proliferation, two-
thirds partial hepatectomy (PH) was performed on 8-week-old
mice. RaptorDhep mice exhibited higher serum alanine amino-
transferase (ALT) (Figure 3A) and marked cytoplasmic clearing
of hepatocytes, indicating hepatocytic damage and aberrant
regeneration with glycogen accumulation, as confirmed by
periodic acid-Shiff (PAS) and PAS diastase (PASD) staining (Fig-
ures 3B, S3A, and S3B). Although liver/body weight ratio of
RaptorDhep mice appeared to be reduced 48 hr after PH, the
effect was not significant (Figure 3A).
Bromodeoxyuridine (BrdU)-incorporating and Ki67-positive
hepatocytes were reduced, but cyclin D1-positive cells were
increased after PH in RaptorDhep mice compared with RaptorF/F
mice (Figure 3C). Since hematoxylin and eosin (H&E) staining re-
vealed fewer mitotic figures in RaptorDhep than in RaptorF/F livers
(Figures 3B and S3A), mitosis was also examined using the
mitotic markers phospho-Histone H3 and cyclin B (Gwinn et al.,Cell Metabolism 20, 1332010; Merlen et al., 2014) (Figure 3D).
The frequency of mitosis after PH was
drastically reduced in RaptorDhep livers,
along with cyclin B, cyclin E, cdc2, p21,
and p27 and elevation of cyclin D1 (Fig-
ure 3E). In addition to p-AKT and p-
GSK3, phosphorylated (activated) ERK
(p-ERK) and STAT3 (p-STAT3) were also
elevated in RaptorDhep livers (Figure 3E).
Taken together, raptor ablation interferes
with hepatocyte proliferation impacting
mainly G2/M transition and mitosis. How-
ever, liver regeneration was not impaired,
and all RaptorDhep mice survived PH,
because hepatocyte overgrowth due topersistent activation of AKT, ERK, and STAT3 and overexpres-
sion of cyclin D1 may have compensated for defective mitosis.
Nonetheless, the raptor deficiency results in damage to the
regenerating liver.
Loss of Raptor Augments Hepatocellular Death and
Inflammation
In addition to being a carcinogen, diethylnitrosamine (DEN) trig-
gers DNA damage, cell death responses, and compensatory pro-
liferation in the liver (Maeda et al., 2005). We injected 8-week-old
RaptorF/F and RaptorDhep males with 100 mg/kg DEN to evaluate
the impact of persistent mTORC1 inhibition on these responses.
RaptorDhep mice exhibited an increase in serum ALT after DEN
challengemore substantial than that ofRaptorF/Fmice (Figure 4A).
Cytoplasmicclearing, indicativeof hepatocytic damage andaber-
rant regeneration with glycogen accumulation, was much more
substantial in DEN-challenged RaptorDhep mice than in RaptorF/F
mice (Figures 4B and S4D). Correspondingly, DEN-challenged
RaptorDhep mice exhibited higher expression of cyclin
D1 (Figures 4F and S4C), higher serum IL-6 (Figure S4A), and
increasedROS accumulation (Figure S4B) compared toRaptorF/F
mice. Thus, whereas short-term rapamycin treatment of obese–144, July 1, 2014 ª2014 Elsevier Inc. 135
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Figure 2. Characterization of Liver-Specific Raptor Knockout Mice
(A) (Left) Raptor PCR on genomic DNA extracted from tail, whole liver, and isolated hepatocytes of WT, RaptorF/+ (F/+), RaptorF/F (F/F or FF), and RaptorDhep (KO)
mice. (Right) immunoblot analysis of isolated hepatocytes from F/F and KO mice with raptor, p70S6K, and its phosphorylation antibody.
(B) Serum ALT and liver weight as a percentage of body weight (LW/BW) in 8-week-old FF and KO mice (n = 4).
(C and D) Staining of liver sections from FF and KO mice with H&E, Sirius red, and F4/80 (C) and B220 and CD3 (D) (scale bar, 100 mm). Sirius red- and F4/80-
positive areas were quantified with ImageJ software and shown as bar graphs (n = 4). B220- and CD3-positive cells were counted and indicated in the bar graphs
(n = 4).
(E) TUNEL and cleaved caspase-3 (clv-casp 3) stainings were performed on liver sections, positive cells were quantified, and results are shown in the bar
graphs (n = 4).
(F) Phospho-gH2AX staining was performed on liver sections, positive cells were quantified, and results are shown in the bar graphs (n = 4).
All the bar graphs in Figure 2 represent means ± SD. See also Figure S2.
Cell Metabolism
Raptor Ablation, Liver Damage, and Tumorigenesis
136 Cell Metabolism 20, 133–144, July 1, 2014 ª2014 Elsevier Inc.
A B
FF KOPH 48hrs
0
5
10
15
20
25
30
35
40
45
FF KO
0
20
40
60
80
100
120
140
160
180
0
20
40
60
80
100
120
140
**
*
*
KOFF
Br
dU
Ki
67
Cy
cl
in
D
1
C
PH 48hrs
Cy
cl
in
B
KOFF
p-
H
H
3
D
0
2
4
6
8
10
12
14
16
0
2
4
6
8
10
12
14 *
*
PH 48hrs
E
0
50
100
150
200
250
300
FF KO
ALT
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
FF KO
LW/BWIU/L %
*
PH 48hrs
FF KO
FF KO FF KO
FF KO
CyclinB
CyclinD1
CyclinE
Cdc2
p27
p21
Tubulin
Raptor
P-p70S6K
P-AKT Ser473
p70S6K
AKT
P-ERK
ERK
P-STAT3
STAT3
P-GSK3 Ser21
GSK3
N.S.
H
E 
x2
00
KO1 KO2FF1 FF2
KO1 KO2FF1 FF2
Figure 3. Loss of Raptor Inhibits Mitosis and Results in Enhanced Liver Damage after Partial Hepatectomy
(A) Serum ALT and liver weight/body weight ratio (LW/BW) in 8-week-old RaptorF/F (FF) and RaptorDhep (KO) mice 48 hr after partial hepatectomy (PH) (n = 3).
(B) Liver sections from FF and KO mice 48 hr after PH were evaluated by H&E staining (magnification bar, 100 mm).
(C) BrdU labeling and immunostaining with antibodies to Ki67 and cyclin D1 at 48 hr after PH. Bar graphs indicate frequencies of BrdU-, Ki67-, and cyclin
D1-positive cells (n = 3).
(D) Phospho-Histone H3 and cyclin B1 staining of liver sections from FF and KO mice after PH, and their quantitative analysis (n = 3).
(E) Immunoblot analysis of liver extracts prepared 48 hr after PH.
All the bar graphs in Figure 3 represent means ± SD. See also Figure S3.
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Figure 4. Loss of Raptor Enhances Hepatocyte Death and Inflammation after DEN Challenge
RaptorF/F (FF) and RaptorDhep (KO) 8-week-old mice were i.p. injected with 100 mg/kg DEN, and their sera and livers were analyzed 24–72 hr later.
(A) Serum ALT after DEN injection (n = 3).
(B and C) Staining of liver sections from FF and KO mice with H&E (B) and Ki67, p-ERK, and cyclin D1 (C) 48 hr after DEN injection (n = 3). Bar graphs indicate
frequencies of Ki67-, p-ERK-, and cyclin D1-positive cells.
(D) Cell death in FF and KO livers was analyzed 48 hr after DEN injection by TUNEL and immunostaining with the antibody against cleaved caspase-3 (clv-casp 3).
Quantitative analysis is shown in the bar graphs (n = 3).
(legend continued on next page)
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Figure 5. Increased DEN-Induced Hepato-
carcinogenesis in RaptorDhep Mice
RaptorF/F (FF) and RaptorDhep (KO) 2-week-old
males were injected with 25 mg/kg DEN. After 4
weeks, mice were separated into two dietary
groups and fed either LFD (FF, KO) or HFD (HFD
FF, HFD KO) until sacrificed at 7 months of age.
Tumor development was analyzed 7 months later.
(A) Gross morphology of livers and typical HCC
histology (magnification bar, 100 mm) inmice of the
indicated genotypes (left panel: DEN-injected
mice kept on LFD; right panel: DEN-injected mice
kept on HFD).
(B) Tumor numbers and maximal tumor sizes (FF,
KO: DEN-injected mice kept on LFD; HFD FF, HFD
KO: DEN-injected mice kept on HFD). Results are
means ± SEM.
(C) Raptor protein expression in tumor and non-
tumor liver tissue was analyzed by immunoblot-
ting. See also Figure S5.
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inhibition enhances liver damage and oxidative stress in the DEN-
challenged liver. Indeed, some ROS accumulation in the raptor-
deficient liver was seen even prior to DEN challenge (Figure S4B).
The numbers of Ki67- and phospho-ERK-positive hepatocytes
were similar, but more cyclin D1-positive hepatocytes were
found in DEN-challenged RaptorDhep livers (Figure 4C). TUNEL
and cleaved caspase-3 staining revealed increased hepatocyte
death in DEN-challenged RaptorDhep mice (Figure 4D). Immuno-
staining for F4/80, B220, andCD3 indicated greater accumulation
of macrophages, B lymphocytes, and T lymphocytes after DEN
administration in RaptorDhep compared to RaptorF/F livers (Fig-
ure 4E). Immunoblotting showed more p-STAT3, p-Akt, p-GSK3,
and cyclinD1, but less p27, in DEN-challenged RaptorDhep livers
(Figure 4F). Expression of mRNAs for IL-6, tumor necrosis factor
(TNF), transforming growth factor b, IL-1b, immune cell markers,
and the cell death mediators DR5, TRB3, TRAIL, and Bim were(E) Immune cell infiltration was analyzed 48 hr after DEN injection by immunostaining with the indicated ant
ImageJ software. B220- and CD3-positive cells were counted (n = 3).
(F) Immunoblot analysis of liver lysates collected after DEN injection.
All the bar graphs in Figure 4 represent means ± SD. See also Figure S4.
Cell Metabolism 20, 133also elevated in the raptor-deficient liver
(Figure S4C). Thus,Raptor ablation poten-
tiated DEN-induced liver damage and
hepatocyte death.
Loss of mTORC1 Activity Enhances
Hepatocarcinogenesis
To determine the role of mTORC1 in
hepatocarcinogenesis, 14-day-old male
RaptorF/F and RaptorDhep mice were in-
jected with 25 mg/kg DEN (Maeda et al.,
2005). At 7 months of age, untreated
mice revealed no spontaneous tumors,
while all mice given DEN developed
typical HCCs (Figure 5A). Strikingly, the
number of detectable tumors wasapproximately 7-fold higher in RaptorDhep mice than in RaptorF/F
mice, and maximal tumor sizes were also higher (Figure 5B).
Raptor expression was markedly reduced in both the nontumor
and tumor portions of RaptorDhep livers (Figure 5C), and the tu-
mors all contained the deletedRaptor allele (Figure S5). To further
characterize the HCCs in RaptorDhep mice, we cultured isolated
HCC cells for several weeks as described (He et al., 2010).
RaptorDhep HCC cells exhibited almost complete loss of raptor
and p-p70S6K and increased p-AKT and enhanced proliferation
relative to dih10 cells, which were established from wild-type
(WT) HCC (Figures S5B and S5C). Treatment of RaptorDhep and
dih10 HCC cells with the AKT inhibitor MK2206 resulted in
inhibition of AKT phosphorylation (Figure S5B). In the raptor-defi-
cientHCCcells, theAKT inhibitor also led to enhancedcaspase-3
cleavage and reduced cell viability (Figures S5B and S5C).
These results suggest that hyperactivation of AKT contributes
to enhanced HCC development in RaptorDhep livers. Importantly,ibodies. F4/80-positive areas were quantified with
–144, July 1, 2014 ª2014 Elsevier Inc. 139
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RaptorDhep mice kept on HFD tended to be higher than those
in low-fat diet (LFD)-fed RaptorDhep mice or HFD-fed RaptorF/F
mice (Figures 5A and 5B). Thus, contrary to our initial expecta-
tions, suppression of mTORC1 activity does not interfere with,
and actually enhances, obesity-promoted HCC development.
Raptor Deficiency Augments Liver Fibrosis and Does
Not Improve Metabolic Parameters in Obese Mice
We analyzed 7-month-old HFD-fed RaptorDhep and RaptorF/F
mice to evaluate the impact of mTORC1 inhibition on obesity-
induced liver pathophysiology. Serum ALT was higher in HFD-
fedRaptorDhepmice than inRaptorF/Fmice (Figure S6A). Although
hepatosteatosis and hepatic TG content were similar in both
groups, the degree of fibrosis in HFD-fed RaptorDhep mice was
significantly higher than that in RaptorF/F mice (Figures 6A–6C).
Glucose tolerance testing revealed that raptor ablation improved
glucose tolerance in LFD-fed mice, but not in HFD-fed mice (Fig-
ure 6D). We also evaluated reduced glutathione (GSH), oxidized
glutathione (GSSG), and GSH/GSSG ratio. Both GSH and the
GSH/GSSG ratio were significantly lower, andGSSGwas higher,
in HFD- and LFD-fed RaptorDhep livers compared to RaptorF/F
livers (Figure S6B).
DISCUSSION
Rapamycin is a potent antiproliferative agent that reverses
many adverse effects associated with chronic mTORC1 activa-
tion. Given frequent mTORC1 activation in cancer, including
50% of HCCs (Bhat et al., 2013), there has been much interest
in the use of rapamycin and rapalogs as anticancer drugs (Cornu
et al., 2013; Guertin and Sabatini, 2007; Menon and Manning,
2008;ShawandCantley, 2006). This interest hasbeenparticularly
high in HCC, because in addition to genetic loss of negative reg-
ulators that function as tumor suppressors, mTORC1 is activated
in response to obesity, which greatly enhances HCC risk in men
(Calle et al., 2003) and mice (Park et al., 2010). Consequently,
we observed that obesity-promoted HCC induction in mice was
accompanied by strong mTORC1 activation and postulated that
together with low-grade inflammation, mTORC1 activation con-
tributes to enhanced hepatocarcinogenesis in obese mice (Park
et al., 2010). We attempted to test this hypothesis by checking
whether rapamycin attenuates obesity-promoted mTORC1 acti-
vation and consequent HCC development. However, we were
surprised to find that even short-term rapamycin treatment re-
sulted in increased IL-6 production and activation within liver tis-
sue of transcription factor STAT3, previously shown to enhance
HCCdevelopment (He et al., 2013). In the course of these studies,
we became aware of reports that rapamycin enhances IL-6 and
TNF and reduces IL-10 expression both in isolatedmacrophages
(Mercalli et al., 2013; Weichhart et al., 2008) and in human (Buron
et al., 2013). To determinewhether these proinflammatory effects
are solely due to mTORC1 inhibition in macrophages, we gener-
atedhepatocyte-specific raptor-deficientmice.Althoughhepato-
cyte-specificmTORC1 activation brought about by Tsc1 ablation
results in spontaneous HCC development (Menon et al., 2012), a
finding we have confirmed (A.U. and M.K., unpublished data),
complete mTORC1 inhibition did not attenuate DEN-induced
HCC development in the absence or presence of dietary obesity.140 Cell Metabolism 20, 133–144, July 1, 2014 ª2014 Elsevier Inc.On the contrary, hepatocyte-specific raptor ablation strongly
potentiated HCC induction in lean and obese mice. Thus,
mTORC1 activation is unlikely to contribute to obesity-promoted
HCC development, at least in this model. Most likely, the cause
of enhanced hepatocarcinogenesis in RaptorDhep mice is the
modest but persistent increase in liver damage and fibrogenesis.
Althoughmodest, this liver damage leads to low-grade inflamma-
tion manifested by elevated macrophage infiltration into the
RaptorDhep liver. Furthermore, liver damage in RaptorDhep mice
is enhanced after PH or DEN administration. Although its exact
cause is not entirely clear, liver damage inRaptorDhepmice is likely
to be due to the absence of the protective function of mTORC1
required for enhanced protein synthesis, as well as defective
mitosis. Activation of AKT may further augment liver damage
and tumorigenesis. Notably, previous studies also revealed tissue
damage, fibrosis, and inflammation upon muscle-specific raptor
ablation, and these effects were not relieved by additional
mTORC2 inactivation, which did not prevent AKT hyperactivation
(Bentzinger et al., 2008). Curiously, sustainedmTORC1 activation
in muscle brought about by Tsc1 ablation also resulted in myop-
athy (Castets et al., 2013), resembling what was found in the liver
(Menon et al., 2012). In conclusion, in addition to enhanced
production of inflammatory cytokines and decreased expres-
sion of IL-10, the adverse effects of long-termmTORC1 inhibition
include elevated liver damage and oxidative stress. Aberrant
liver regeneration, also seenafter rapamycinor temsirolimus treat-
ment (Espeillac et al., 2011) and in RaptorDhep livers, is another
reason to be concerned about long-term rapalog use, because
live-donor liver transplantation, which requires regeneration, is a
major treatment option for advanced NASH and localized HCC.
Although rapamycin prevents spontaneous liver damage,
fibrosis, and tumorigenesis in hepatocyte-specific Tsc1
knockout mice (Menon et al., 2012), in normal mice, even those
that are kept on HFD, the adverse effects of mTORC1 inhibition
outweigh the benefits. Although temporary mTORC1 inhibition
reduced hepatosteatosis in HFD-fed mice, after 7 months of
hepatocyte-specific raptor ablation, obesity-driven hepatostea-
tosis and glucose intolerance were not ameliorated. These ef-
fects are comparable to clinical findings, according to which
60%of patients receiving rapalogs require lipid-lowering therapy
and are at a higher risk for posttransplant diabetes (Barlow et al.,
2013; Peddi et al., 2013). Recently, increased liver damage was
also observed during clinical testing of an active-site second-
generation mTOR inhibitor (Matter et al., 2014). Since some of
the adverse effects of mTORC1 activation may be due to hyper-
activation of AKT and inhibition of autophagy, other approaches
for inhibiting AKT activity and enhancing autophagic clearance of
lipid droplets (Singh et al., 2009) may be more suitable for
reducing the risk of obesity-promoted NASH and HCC develop-
ment, a rapidly growing public health problem.
EXPERIMENTAL PROCEDURES
Animals and Liver Analysis
RaptorF/Fmiceweregeneratedasdescribedpreviously (Bentzinger et al., 2008),
backcrossed to C57BL/6 mice at least seven generations, and bred with
Alb-Cre transgenicmice to generateRaptorF/F;Alb-Cre (RaptorDhep)mice.Gen-
otyping was performed as described previously (Bentzinger et al., 2008).
All animal studies were performed in accordance with NIH guidelines for
the use and care of live animals and approved by University of California,
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Figure 6. Hepatocyte Raptor Ablation Does Not Reduce Hepatosteatosis and Augments Liver Fibrosis in HFD-Fed Mice
RaptorF/F (FF) and RaptorDhep (KO) mice were kept on HFD or LFD for 6 months.
(A) Liver histology, lipid accumulation, and fibrosis were analyzed by staining liver sections with H&E, oil red O, Sirius red, and a smooth muscle actin (SMA)
antibody. The positive areas were quantified with ImageJ software and shown as bar graphs.
(B) Liver triglyceride (TG) content in 7-month-old mice kept on LFD or HFD.
(C) The mRNA amounts of fibrogenic markers, collagen a1(I) (Col1A1), collagen a1(IV) (Col4A1), actin a2 (Acta2), and tissue inhibitor of metalloproteinase 1
(Timp1) in livers of 7-month-old FF and KO mice were determined by real-time quantitative PCR (qPCR).
(D) Glucose tolerance tests were performed on 7-month-old FF and KO mice kept on LFD or HFD (n = 4).
All the bar graphs in Figure 6 represent means ± SD. See also Figure S6.
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Raptor Ablation, Liver Damage, and TumorigenesisSan Diego (UCSD) Institutional Animal Care and Use Committee, S00218. All
mice were maintained in filter-topped cages on autoclaved chow diet (low-
fat diet, LFD; composed of 12% fat, 23% protein, and 65% carbohydrates
based on caloric content) or high-fat diet (HFD; composed of 59% fat, 15%
protein, and 26% carbohydrates based on caloric content; BioServ) and water
at UCSD according to NIH guidelines.
In the DEN-induced HCCmodel, DEN (25mg/kg) was injected intraperitone-
ally (i.p.) into 14-day-old male mice. After 4 weeks, mice were separated into
two dietary groups and fed either LFD or HFD until sacrificed at 7 months
of age. In the DEN-induced acute liver injury model, DEN (100 mg/kg) was
i.p. injected into 8-week-old mice.
All mice were sacrificed, and their livers were removed and separated
into individual lobes. Externally visible tumors (>1 mm) were counted
and measured. Large lobes were fixed in 10% formalin for 24–48 hr or
embedded in Tissue-Tek OCT compound (Sakura Finetek) for paraffin or
frozen block preparation, respectively. Frozen tissue sections were stained
with oil red O (ORO) for lipid, dihydroethidine (DHE) for ROS, and anti-
smooth muscle actin (SMA) antibody (Abcam) for fibrosis detection.
Paraffin-embedded liver tissues were used for H&E, TUNEL, BrdU, PAS,
PASD, and immunostaining, but not for SMA staining. A board-certified
pathologist (M.V.) evaluated all histologic sections. Antibodies used were
against phospho-Histone H3, phospho-gH2AX, cyclin D1, cleaved cas-
pase-3, phospho-ERK (all from Cell Signaling), F4/80 (Caltag), B220
(eBioscience), and CD3 (Dako). Sirius red staining was performed to quan-
titate the amount of collagen fibers. Apoptosis was determined by the
ApoAlert TUNEL Assay Kit (Clontech). To examine cell proliferation, mice
were i.p. injected with 100 mg/kg BrdU (Sigma) 2 hr prior to sacrifice, and
paraffin sections were stained using the BrdU in situ detection kit (BD
Biosciences). To detect glycogen accumulation, PAS and PASD staining
were performed. ORO-, Sirius red-, SMA-, F4/80-, and DHE-positive areas
were quantified using ImageJ software. B220-, CD3-, TUNEL-, cleaved cas-
pase-3-, p-gH2AX-, Ki67-, p-ERK-, cyclin D1-, BrdU-, p-HH3-, and cyclin
B-positive cells were counted in 6–10 random fields ( 3100, 3200,
or 3400) on each slide. All of the quantification results are depicted in the
bar graphs on the right side of each panel. All the scale bars indicate
100 mm. Remaining lobes were microdissected into tumor and nontumor
tissue and stored at 80C until analyzed.
Glucose Tolerance Test
For glucose tolerance test, mice were starved for 6 hr. Blood was drawn from a
tail nick at the indicated time points after i.p. injection of glucose (2 g/kg body
weight), and blood glucose was instantly measured by one-touch ultra glucose
meter.
Protein Immunoblotting
Liver samples were homogenized in RIPA buffer, and then equal amounts
of liver homogenates were fractionated by SDS-PAGE and transferred onto
a polyvinylidene fluoride (PVDF) membrane. The membrane was incubated
with antibodies to raptor, phospho-STAT3, phospho-Akt, phospho-ERK,
ERK, phospho-GSK3a/b, GSK3, cyclin D1, LC3 (all from Cell signaling), phos-
pho-p70S6K, p70S6K, cyclin B, cyclin E, cdc2, p27, STAT3 (all from Santa
Cruz), tubulin (Sigma), p62 (Progen), and p21 (Chemicon).
RNA Isolation and Real-Time PCR
We extracted total RNA by TRIzol (Invitrogen). RNA (1 mg) was used to
generate cDNA with iScript cDNA Synthesis Kit (Bio-Rad). Individual gene
expression was quantified by SYBR Green Supermix and CFX96 Real-Time
PCR system (Bio-Rad) and normalized to a housekeeping control gene, either
cyclophilin or GAPDH. Primer sequences for Real-time PCR are available
upon request.
Determination of IL-6 and ALT Levels
Serum IL-6 was measured by ELISA (BD Biosciences), and ALT was detected
using Infinity reagent (Thermo Scientific).
Liver Triglyceride Measurement
We extracted lipids from liver tissues by the Folch method. Triglyceride (TG)
contents were measured with Pointe Scientifc Triglycerides Reagent.142 Cell Metabolism 20, 133–144, July 1, 2014 ª2014 Elsevier Inc.Isolation and Culturing of Primary Mouse Hepatocytes and HCC
Cells
AML12 cells were maintained according to ATCC’s instructions and incubated
with rapamycin (Alfa Aesar) as indicated. Primary hepatocytes were isolated
from 8- to 12-week-old RaptorF/F and RaptorDhep mice using collagenase
perfusion as described previously (Leffert et al., 1979). Isolated hepatocytes
were resuspended in William’s E medium and plated on collagen I-coated
plates in medium with serum. Cells were incubated overnight, followed by
protein extraction and genomic DNA analysis. DEN-induced HCC cells were
isolated and cultured from a RaptorDhep mouse and compared to dih10 HCC
cells, which were established from DEN-induced HCC in a WT BL6 mouse
(He et al., 2010). Relative cell viability/proliferation was determined using
Cell Counting Kit-8 (Dojindo Laboratories).
Statistical Analysis
Data are presented as means ± SD or means ± SEM, as indicated. Differences
in means were analyzed by Student’s t test and one-way ANOVA. p values <
0.05 were considered significant (not significant [N.S.]: p > 0.05, *p < 0.05,
**p < 0.01).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2014.05.001.
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